MedTrace Logo

Observational Prospective Registry of the Efficacy, Safety, and Adherence to Infergen® in Patients Infected With Hep C

NCT00951223 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2015-09-03

No results posted yet for this study

Summary

This observational prospective registry is designed to evaluate the safety, adherence, and efficacy of prescribed, patient-administered therapy with Infergen® (Interferon alfacon 1) and other prescribed therapies in patients chronically infected with HCV. The primary endpoint for efficacy will be the SVR rate at 24 weeks after therapy ends.

Conditions

  • Hepatitis C

Interventions

DRUG

Infergen® (Interferon alfacon-1)

Infergen at either the 15 mcg or 9 mcg dose given per Providers instructions, with or without weight based ribavirin

Sponsors & Collaborators

  • Kadmon Corporation, LLC

    lead INDUSTRY

Principal Investigators

  • Andrew Muir, MD · DCRI

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2010-11-30
Completion
2011-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00951223 on ClinicalTrials.gov